Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Maria Lia Palomba, MD, Leo I. Gordon, MD, Tanya Siddiqi, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Jon E. Arnason, MD, Nilanjan Ghosh, MD PhD, Amitkumar Mehta, MD, Scott R. Solomon, MD, Thalia Farazi, MD PhD, Jacob Garcia, MD, Christine Dehner, BSc, Ken Ogasawara, PhD MPH, Jie Gao, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136158

Published: 2020

Journal Articles

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

M. Lia Palomba, MD, Monika P. Jun, MPH, Jacob Garcia, MD, James Lymp, PhD, November McGarvey, Matthew Gitlin, Corey Pelletier, Andy Nguyen

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-141415

Published: 2020

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, Jacob Garcia, MD, Christine Dehner, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 66.

https://doi.org/10.1182/blood-2019-127145

Published: 2019

Journal Articles

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

David G. Maloney, MD PhD, Fei Fei Liu, Lisette Nientker, Cathelijne Alleman, Brian Hutton, PhD, Jacob Garcia, MD

Blood (2019) 134 (Supplement_1): 5821.

https://doi.org/10.1182/blood-2019-127664

Published: 2019

Journal Articles

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

Tanya Siddiqi, MD, Jacob Garcia, MD, Christine Dehner, Andy Nguyen, PhD, Matthew Gitlin, PharmD, Karen C. Chung, PharmD, MS, Jeremy S. Abramson, MD MMSc

Blood (2018) 132 (Supplement 1): 319.

https://doi.org/10.1182/blood-2018-99-112214

Published: 2018

Journal Articles

TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

M. Lia Palomba, MD, Jacob Garcia, MD, Lei Wang, PhD, Christine Dehner, Karen C. Chung, PharmD, MS, David G. Maloney, MD PhD

Blood (2018) 132 (Supplement 1): 3545.

https://doi.org/10.1182/blood-2018-99-119387

Published: 2018

Journal Articles

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Mark Heipel, BSc, Jeffrey Smith, BA, William Brown, MAS, Mandana Karimi, MSc, Benhuai Xie, PhD, Daniel Li, PhD, Tina Albertson, MD, Jacob Garcia, MD, Todd Devries, PhD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 2835.

https://doi.org/10.1182/blood.V130.Suppl_1.2835.2835

Published: 2017

Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 193.

https://doi.org/10.1182/blood.V130.Suppl_1.193.193

Published: 2017

Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 1552.

https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552

Published: 2017

Journal Articles

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 581.

https://doi.org/10.1182/blood.V130.Suppl_1.581.581

Published: 2017

Journal Articles

Geographic Access to Oncology Services in the United States (US): Travel Disparities May Affect Granulocyte-Colony Stimulating Factor (G-CSF) Administration

Mark Stephens, Mark Bensink, PhD MS, Samuel Brotherton, David Chandler, PhD MBA, Jacob Garcia, MD, Christopher Hollenbeak, PhD

Blood (2016) 128 (22): 5905.

https://doi.org/10.1182/blood.V128.22.5905.5905

Published: 2016

Journal Articles

Cost Differences of Same-Day Vs Next-Day Use of Pegfilgrastim

Xiaoyan Li, PhD, Xinke Zhang, MS, Junji Lin, PhD, Kelly Fust, MS, Jacob Garcia, MD

Blood (2015) 126 (23): 5566.

https://doi.org/10.1182/blood.V126.23.5566.5566

Published: 2015

Journal Articles

Same-Day Administration of Pegfilgrastim Following Myelosuppressive Chemotherapy: Practices and Rationale

Christina Darden, Mark A. Price, James A. Kaye, MD DrPH, Bintu Sherif, Sarah Marion, Spiros Tzivelekis, MSc, Jacob Garcia, MD, David Chandler

Blood (2015) 126 (23): 5585.

https://doi.org/10.1182/blood.V126.23.5585.5585

Published: 2015

Journal Articles

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Derek Weycker, PhD, Xiaoyan Li, PhD, Rich Barron, M.S., Hongsheng Wu, PhD, Phuong Khanh Morrow, MD, Hairong Xu, MD, PhD, Maureen Reiner, M.S., Jacob Garcia, MD, Shivani Mhatre, M.S., Gary H. Lyman, MD MPH

Blood (2014) 124 (21): 4824.

https://doi.org/10.1182/blood.V124.21.4824.4824

Published: 2014

NARROW

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Geographic Access to Oncology Services in the United States (US): Travel Disparities May Affect Granulocyte-Colony Stimulating Factor (G-CSF) Administration

Cost Differences of Same-Day Vs Next-Day Use of Pegfilgrastim

Same-Day Administration of Pegfilgrastim Following Myelosuppressive Chemotherapy: Practices and Rationale

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only